These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37701966)

  • 1. Next-generation proteomics technologies in Alzheimer's disease: from clinical research to routine diagnostics.
    Weiner S; Blennow K; Zetterberg H; Gobom J
    Expert Rev Proteomics; 2023; 20(7-9):143-150. PubMed ID: 37701966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids.
    Korecka M; Shaw LM
    J Neurochem; 2021 Oct; 159(2):211-233. PubMed ID: 34244999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.
    Liu Y; Qing H; Deng Y
    Int J Mol Sci; 2014 May; 15(5):7865-82. PubMed ID: 24806343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.
    Robinson RA; Amin B; Guest PC
    Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.
    Cilento EM; Jin L; Stewart T; Shi M; Sheng L; Zhang J
    J Neurochem; 2019 Nov; 151(4):397-416. PubMed ID: 30474862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting Alzheimer's Disease Molecular Substrates by Proteomics and Discovery of Novel Post-translational Modifications.
    Deolankar SC; Patil AH; Koyangana SG; Subbannayya Y; Prasad TSK; Modi PK
    OMICS; 2019 Jul; 23(7):350-361. PubMed ID: 31225774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroproteomic tools for battling Alzheimer's disease.
    Veenstra TD
    Proteomics; 2016 Nov; 16(22):2847-2853. PubMed ID: 27633846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Proteomics Biomarkers in Alzheimer's Disease: Latest Advances and Challenges.
    Perneczky R; Guo LH
    Methods Mol Biol; 2016; 1303():521-9. PubMed ID: 26235089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multiplexed Urinary Biomarker Panel Has Potential for Alzheimer's Disease Diagnosis Using Targeted Proteomics and Machine Learning.
    Hällqvist J; Pinto RC; Heywood WE; Cordey J; Foulkes AJM; Slattery CF; Leckey CA; Murphy EC; Zetterberg H; Schott JM; Mills K; Paterson RW
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers.
    Lovestone S; Güntert A; Hye A; Lynham S; Thambisetty M; Ward M
    Expert Rev Proteomics; 2007 Apr; 4(2):227-38. PubMed ID: 17425458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroproteomics tools in clinical practice.
    Shevchenko G; Konzer A; Musunuri S; Bergquist J
    Biochim Biophys Acta; 2015 Jul; 1854(7):705-17. PubMed ID: 25680928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted and Untargeted Proteomics Approaches in Biomarker Development.
    Sobsey CA; Ibrahim S; Richard VR; Gaspar V; Mitsa G; Lacasse V; Zahedi RP; Batist G; Borchers CH
    Proteomics; 2020 May; 20(9):e1900029. PubMed ID: 31729135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease.
    Kodosaki E; Zetterberg H; Heslegrave A
    Expert Rev Mol Diagn; 2023; 23(12):1153-1165. PubMed ID: 38018372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving Relevance of Neuroproteomics in Alzheimer's Disease.
    Lista S; Zetterberg H; O'Bryant SE; Blennow K; Hampel H
    Methods Mol Biol; 2017; 1598():101-115. PubMed ID: 28508359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MS-DAP Platform for Downstream Data Analysis of Label-Free Proteomics Uncovers Optimal Workflows in Benchmark Data Sets and Increased Sensitivity in Analysis of Alzheimer's Biomarker Data.
    Koopmans F; Li KW; Klaassen RV; Smit AB
    J Proteome Res; 2023 Feb; 22(2):374-386. PubMed ID: 36541440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.
    Findeisen P; Neumaier M
    Clin Chem Lab Med; 2009; 47(6):666-84. PubMed ID: 19445650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted proteomics for quantification of histone acetylation in Alzheimer's disease.
    Zhang K; Schrag M; Crofton A; Trivedi R; Vinters H; Kirsch W
    Proteomics; 2012 Apr; 12(8):1261-8. PubMed ID: 22577027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in mass spectrometry-based cancer research and analysis: from cancer proteomics to clinical diagnostics.
    Timms JF; Hale OJ; Cramer R
    Expert Rev Proteomics; 2016 Jun; 13(6):593-607. PubMed ID: 27109265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.